moatshark My

All holdings

Bio-Techne

TECH

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
3
In their latest 13F (Q3 2026)
See who
Value held
$466m
Combined value at quarter end
Last quarter
0 bought
3 sold or trimmed
Fund portfolios
6
Funds holding it
See which
Price at Q2 ’26 end
$70.65
+35.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+11.6%Q3 ’24
-9.9%Q4 ’24
-18.6%Q1 ’25
-12.2%Q2 ’25
+8.1%Q3 ’25
+5.7%Q4 ’25
-11.1%Q1 ’26
+35.2%Q2 ’26
Q3 ’24: +11.6%; Q4 ’24: -9.9%; Q1 ’25: -18.6%; Q2 ’25: -12.2%; Q3 ’25: +8.1%; Q4 ’25: +5.7%; Q1 ’26: -11.1%; Q2 ’26: +35.2%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

3Q4 ’23
3Q1 ’24
4Q2 ’24
4Q3 ’24
4Q4 ’24
4Q1 ’25
4Q2 ’25
3Q3 ’25
3Q4 ’25
3Q1 ’26
3Q2 ’26
0Q3 ’26
Q4 ’23: 3; Q1 ’24: 3; Q2 ’24: 4; Q3 ’24: 4; Q4 ’24: 4; Q1 ’25: 4; Q2 ’25: 4; Q3 ’25: 3; Q4 ’25: 3; Q1 ’26: 3; Q2 ’26: 3; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Bio-Techne.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Bio-Techne
Ruane, Cunniff & Goldfarb (Sequoia)3.7%$237m$237mTrimmed -1.3%5 qtrs
Weitz Investment Management2.7%$38.4m$38.4mTrimmed -17%9 qtrs
Mairs & Power1.8%$191m$191mTrimmed -1.8%48 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Minnesota
Financial year ends
30 June
Shares outstanding
157m at 17 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$358mJun ’14
$499mJun ’16
$643mJun ’18
$739mJun ’20
$1.1bnJun ’22
$1.2bnJun ’24
$1.2bnJun ’26
Jun ’13: $311m; Jun ’14: $358m; Jun ’15: $452m; Jun ’16: $499m; Jun ’17: $563m; Jun ’18: $643m; Jun ’19: $714m; Jun ’20: $739m; Jun ’21: $931m; Jun ’22: $1.1bn; Jun ’23: $1.1bn; Jun ’24: $1.2bn; Jun ’25: $1.2bn; Jun ’26: $1.2bn
Bio-Techne revenue and net income by year
YearRevenueNet income
Year to Jun 2026$1.2bn–
Year to Jun 2025$1.2bn$73.4m
Year to Jun 2024$1.2bn$168m
Year to Jun 2023$1.1bn$285m
Year to Jun 2022$1.1bn$272m
Year to Jun 2021$931m$140m
Year to Jun 2020$739m$229m
Year to Jun 2019$714m$96.1m
Year to Jun 2018$643m$126m
Year to Jun 2017$563m$76.1m
Year to Jun 2016$499m$104m
Year to Jun 2015$452m$108m
Year to Jun 2014$358m$111m
Year to Jun 2013$311m$113m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Bio-Techne, from their latest N-PORT filings.

Funds holding Bio-Techne
Mairs & Power Small Cap FundMairs & Power3.9%$10.6m30 Jun 2026
Sequoia FundRuane, Cunniff & Goldfarb (Sequoia)2.7%$97.9m30 Jun 2026
Weitz Partners Value FundWeitz Investment Management2.6%$12.7m30 Jun 2026
Weitz Partners III Opportunity FundWeitz Investment Management2.5%$8.5m30 Jun 2026
Weitz Large Cap Equity FundWeitz Investment Management2.3%$14.1m30 Jun 2026
Mairs & Power Growth FundMairs & Power1.8%$99.3m30 Jun 2026